|
|
JACKSON CENTER, PA / ACCESSWIRE / April 11, 2022 / Halberd Corporation OTC PINK:HALB announces plans to enter the Metaverse by the creation of nonfungible tokens NFTs to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc.Halberd is currently in negotiations to engage a team of experts in Metaverse with expertise in... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / April 4, 2022 / Halberd Corporation OTC PINK:HALB demonstrated the extracorporeal elimination of CReactive Protein from cerebral spinal fluid CSF by exposure to tuned laser light, in vitro. Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD Post Traumatic Stress Disorder, CTE Chronic Traumatic Encephalopathy... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / March 16, 2022 / Halberd Corporation OTC PINK:HALB announces its entry into the next stage of research. To guide it, having successfully eliminated the Top 10 Target Antigens associated with neurodegenerative diseases in vitro, Halberd is pleased to announce the addition of Ravi Venkata Durvasula, M.D., a renowned infectious disease specialist and educator, to... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / March 8, 2022 / Halberd Corporation OTC PINK:HALB is pleased to announce Youngstown State Universitys YSU Dr. Chester R. Cooper has joined its technical team. Dr. Cooper currently holds the position of Professor, Department of Biological Sciences, at Youngstown State University. Dr. Cooper has been a valuable resource in Halberds work at the university in the... Lire le communiqué |
|
| |
|
| |
|
|
Outperforms Approved COVID AntibodiesJACKSON CENTER, PA / ACCESSWIRE / March 1, 2022 / Halberd Corporations OTC PINK:HALB previously developed SARSCoV2 antibody demonstrated superior binding capability to the SARSCoV2 Omicron variant disease antigen. The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization EUA COVID... Lire le communiqué |
|
| |
|
| |
|
|
JACKSON CENTER, PA / ACCESSWIRE / February 22, 2022 / Halberd Corporation OTC PINK:HALB has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination of glutamate from cerebral spinal fluid CSF, Halberd has demonstrated the capability to control each of the top ten neurodegenerative diseaseassociated antigens. See Table Below. This could lead to... Lire le communiqué |
|
| |
|
| |
|
|
Tau buildup in the brain is linked to Alzheimers and other neurodegenerative diseases.JACKSON CENTER, PA / ACCESSWIRE / February 8, 2022 / Halberd Corporation OTC PINK:HALB has demonstrated the ability to eliminate 100% of Tau protein from cerebral spinal fluid CSF in less than 20 minutes with its patented extracorporeal laser exposure process. Excess Tau in CSF is associated with the onset an... Lire le communiqué |
|
| |
|
| |
